CELLULAR BIOMEDICINE GROUP, INC. Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2020-09-30..
Gross margin
Overview →Financial period ending 2020-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2020-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 322.95K USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2020-09-30 | (m) | $322.95K | (m) | (m) |
| 2020-06-30 | (m) | $290.65K | (m) | (m) |
| 2020-03-31 | (m) | $290.65K | (m) | (m) |
| 2019-12-31 | $277.54K | $339.92K | (m) | 81.65% |
| 2019-09-30 | $45.29K | (m) | (m) | (m) |
| 2019-06-30 | $78.24K | (m) | (m) | (m) |
| 2019-03-31 | $101.16K | (m) | (m) | (m) |
| 2018-12-31 | $88.64K | $224.40K | (m) | 39.50% |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $289.35K | (m) | (m) |
| 2017-12-31 | (m) | $336.82K | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $237.86K | (m) | (m) |
| 2016-12-31 | $-232.49K | $627.93K | (m) | -37.02% |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) |
| 2016-03-31 | $501.06K | $2.39M | (m) | 20.96% |
| 2015-12-31 | $625.09K | $2.51M | (m) | 24.95% |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | $411.04K | $1.11M | (m) | 37.14% |
| 2014-12-31 | $322.16K | $564.38K | (m) | 57.08% |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-91.30K | $204.91K | (m) | -44.55% |
| 2013-09-30 | $12.38M | $12.42M | (m) | 99.69% |
| 2013-06-30 | $9.35M | $9.24M | (m) | 101.22% |
| 2012-12-31 | $9.40M | $9.40M | (m) | 100.00% |
| 2012-09-30 | $411.80K | $531.91K | (m) | 77.42% |
| 2012-06-30 | $417.81K | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | $285.50K | $285.50K | (m) | 100.00% |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.74M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.